

November 13, 2020

Company name: Nikkiso Co., Ltd.
Representative: Toshihiko Kai, President & CEO
(Stock code: 6376 First section of the Tokyo Stock Exchange)
Contact: Susumu Koito, Director, General Manager of Corporate Unit
(Tel. +81-3-3443-3717)

Notice regarding the Establishment of a Subsidiary (Second-generation Subsidiary) in the U.S.

Nikkiso Co., Ltd. (“NIKKISO”) hereby announces that its Board of Directors decided to establish a subsidiary (second-generation subsidiary) in the U.S. as follows.

1. Purpose of establishment

In order to propose comfortable, safe and assuring dialysis medical care for everyone who requires hemodialysis treatment, NIKKISO consistently performs operations from development, manufacturing and sales, to maintenance. With a view to establishing a structure that includes marketing, sales, maintenance services and training to promptly accommodate the needs of customers also in the U.S., we have decided to establish this subsidiary. NIKKISO will strive to expand the hemodialysis business in the U.S. market through the subsidiary.

2. Profile of subsidiary

(1)	Company name	Nikkiso Medical America, Inc.
(2)	Location	Memphis, Tennessee, U.S.A.
(3)	Name and title of representative	Hisanao Amino, CEO
(4)	Business activities	Import, sale and maintenance of hemodialysis-related products in the U.S.
(5)	Paid-in capital	USD 1
(6)	Date of establishment	December 2020 (plan)
(7)	Principal shareholder	Nikkiso America, Inc. (wholly-owned consolidated subsidiary of NIKKISO): 100%

3. Impact on business performance

The impact on the consolidated results of operations for the current fiscal year is minimal. If any matter that should be disclosed arises going forward, we will promptly make the disclosure.